LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Aktien・Simulations Plus Inc

Simulations Plus Inc

Geschlossen

BrancheGesundheitswesen

16.57 3.24

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

16.06

Max

17.03

Schlüsselkennzahlen
By Trading Economics
Einkommen	3.9M 4.5M
Verkäufe	5.9M 24M
EPS	0.35
Gewinnspanne	18.669
Angestellte	212
EBITDA	4.9M 7.2M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	-1.05% downside

Dividenden
By Dow Jones
Nächstes Ergebnis	13. Juli 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	107M 358M
Vorheriger Eröffnungskurs	13.33
Vorheriger Schlusskurs	16.57

Nachrichtenstimmung

By Acuity

80%

20%

315 / 344 Ranking in Healthcare

Simulations Plus Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Simulations Plus Inc Prognose

Kursziel

By TipRanks

-1.05% Nachteil

12-Monats-Prognose

Durchschnitt 16 USD -1.05%

Hoch 16 USD

Tief 16 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Simulations Plus Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

3 ratings

Buy

Halten

Sell

Basierend auf 3 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Simulations Plus Inc – Dist abgegeben haben.

Stimmung

By Acuity

315 / 344 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.